[Korea Biomedical Review]

Regulator OKs Genencell’s P2, 3 trials for oral Covid-19 treatment

Genencell said that the Ministry of Food and Drug Safety has approved the company’s investigational new drug (IND) application to conduct phase 2 and 3 clinical trials for ES16001, an oral Covid-19 treatment.
Genencell explained that the ministry’s approval signals the official start of global clinical trials for its oral Covid-19 treatment.
“As the company has confirmed the safety and efficacy in preclinical studies, local phase 1 clinical trial, and India phase 2a trial, the company expects to produce positive results in phase 2 and 3 clinical trials as well,”

http://www.koreabiomed.com/news/articleView.html?idxno=12428